A single booster shot of MenQuadfi can be given to people ages 13 years or older who are at a continued risk of IMD if it’s been at least three years since their last meningococcal vaccine.

Also active in the category is Sanofi, which sells MenACWY vaccines Menactra and MenQuadfi, lacking coverage of the B serogroup considered the most common cause of meningococcal disease in the US.

On May 23, 2025, the FDA expanded the approval of MenQuadfi (Sanofi) to include infants aged 6 weeks to 23 months for the prevention of meningococcal disease. MenQuadfi is now the only quadrivalent ...

The hyperpolarized contrast agent for oral inhalation can now be used in patients 6 years and older, lowering the approved indication from 12 years of age. On June 2, 2025, the FDA approved a ...

The "United States Vaccines Market Size, Top 47 Vaccines Brand In-depth Analysis, Insights, and Forecasts to 2033" report has been added to ResearchAndMarkets.com's offering. The United States ...